akebia therapeutics stock forecast

View insider buying and selling activity for Akebia Therapeutics. Akebia Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 AKBA stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Morgan Stanley, Squarepoint Ops LLC, Acadian Asset Management LLC, BlackRock Inc., SG Americas Securities LLC, AQR Capital Management LLC, and DekaBank Deutsche Girozentrale. Following the recent earnings report, the consensus from eight analysts covering Akebia Therapeutics is for revenues of US$240.2m in 2021, implying a stressful 22% … MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX), Gilead Sciences (GILD), AbbVie (ABBV), Energy Transfer (ET), Micron Technology (MU), TherapeuticsMD (TXMD), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), NVIDIA (NVDA) and AT&T (T). Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Akebia Therapeutics stock price target cut to $6 from $17 at Mizuho Sep. 4, 2020 at 6:22 a.m. Analysts forecast that Akebia Therapeutics will post -1.5 earnings per share for the current year. Company insiders that have sold Akebia Therapeutics company stock in the last year include Dell Faulkingham, Jason Amello, Maxine Gowen, Michel Dahan, and Nicole R Hadas. Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. View our full suite of financial calendars and market data tables, all for free. Akebia Therapeutics has a market capitalization of $478.42 million and generates $335 million in revenue each year. Investors in Akebia Therapeutics, Inc. AKBA need to pay close attention to the stock based on moves in the options market lately. Find real-time AKBA - Akebia Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. According to 6 Wall Street analysts that have issued a 1 year AKBA price target, the average AKBA price target is $10.17, with the highest AKBA stock price forecast at $18.00 and the lowest AKBA stock price forecast at $3.00. Akebia Therapeutics' stock is owned by a number of institutional and retail investors. I saw some exciting stuff about Akebia Therapeutics for example I saw a few different stock forecasts giving it a forecast of $6 or even more (currently trades at $2.22). © American Consumer News, LLC dba MarketBeat® 2010-2020. In 2022, AKBA is forecast to generate $-62,343,072 in earnings, with the lowest earnings forecast at $-110,354,403 and the highest earnings forecast at $2,866,348. View all competitors. Great Point Partners LLC acquired a new position in shares of Akebia Therapeutics in the 2nd quarter valued at $47,667,000. What this means: InvestorsObserver gives Akebia Therapeutics Inc (AKBA) an overall rank of 34, which is below average. Company insiders that have bought Akebia Therapeutics stock in the last two years include John P Butler, Steven C Gilman, and Steven Keith Burke. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. Please log in to your account or sign up in order to add this asset to your watchlist. 7 Wall Street analysts have issued ratings and price targets for Akebia Therapeutics in the last 12 months. Their average twelve-month price target is $10.29, predicting that the stock has a possible upside of 203.41%. MarketBeat's community ratings are surveys of what our community members think about Akebia Therapeutics and other stocks. Akebia Therapeutics, Inc. (NASDAQ:AKBA) announced its quarterly earnings results on Tuesday, November, 10th. Similar to Selecta, Akebia Therapeutics Inc. ( AKBA Stock Report ) also fell earlier this year after bad news. Are Disney Layoffs a Signal to Lay off the Stock? The average price target is $6.71 with a high forecast of $10.00 and a low forecast of $3.00.The average price target represents a 103.33% increase from the last price of $3.30. Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. View institutional ownership trends for Akebia Therapeutics. Akebia Therapeutics' management team includes the following people: Start Your Risk-Free Trial Subscription Here, Moderna (NASDAQ:MRNA) Makes Explosive Gains in Pre-Market, The Top Two Sectors For The Q4 Earnings Season. Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™ November 16, 2020 Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials All rights reserved. WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. © 2020 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. The consensus among 6 Wall Street analysts covering (NASDAQ: AKBA) stock is to Strong Buy AKBA stock. As can be gleaned from the statistics, the company’s share value dive -76.3% over the past 6 months, a 11.44% in annual growth rate that is considerably lower than the industry average of 15.4%. Get the latest Akebia Therapeutics, Inc. AKBA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. It's shaping up to be a tough period for Akebia Therapeutics, Inc. (NASDAQ:AKBA), which a week ago released some disappointing third-quarter results that could have a notable impact on how the market views the stock.Statutory earnings fell substantially short of expectations, with revenues of US$60m missing forecasts by 33%. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. In the medium term (3months), AKBA's stock price should outperform the market by 7.18%. (Add your “outperform” vote. Akebia Therapeutics, Inc. () Stock Market info Recommendations: Buy or sell Akebia Therapeutics stock? (NASDAQ: AKBA) Akebia Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of -1.59%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 12.63%. Akebia Therapeutics has received 388 “outperform” votes. Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA.". See what's happening in the market right now with MarketBeat's real-time news feed. What is AKBA's revenue growth forecast for 2020-2022? What is AKBA's Earnings Per Share (EPS) forecast for 2020-2022? Shares of AKBA can be purchased through any online brokerage account. Some companies that are related to Akebia Therapeutics include Intra-Cellular Therapies (ITCI), Ironwood Pharmaceuticals (IRWD), Madrigal Pharmaceuticals (MDGL), Prestige Consumer Healthcare (PBH), Rocket Pharmaceuticals (RCKT), Dicerna Pharmaceuticals (DRNA), Stoke Therapeutics (STOK), Mersana Therapeutics (MRSN), Arcus Biosciences (RCUS), Revance Therapeutics (RVNC), NGM Biopharmaceuticals (NGM), Heron Therapeutics (HRTX), CytoDyn (CYDY), Keros Therapeutics (KROS) and Zealand Pharma A/S (ZEAL). The Michaels Companies (NYSE: MIK) Stock is a Dual Narrative Play, Organigram (NASDAQ:OGI) Rockets Higher After Q4 Earnings, FuelCell (NASDAQ: FCL) Stock is an Alternative Energy Pullback Buy at These Levels. AKBA Stock Analysis Overview . Get daily stock ideas top-performing Wall Street analysts. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Penny Stocks To Buy [according to HC Wainwright]: Akebia Therapeutics Inc. Akebia Therapeutics has received a consensus rating of Buy. The firm has a Buy on the stock with an SELB stock forecast of $6. Akebia Therapeutics, Inc. Stock Price Forecast, "AKBA" Predictons for2020 Learn more. Akebia Therapeutics' stock was trading at $6.94 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). During the day the stock fluctuated 10.87% from a day low at $2.30 to a day high of $2.55. Top institutional shareholders include State Street Corp (10.70%), BlackRock Inc. (8.19%), Nantahala Capital Management LLC (3.98%), Morgan Stanley (0.83%), Squarepoint Ops LLC (0.71%) and Charles Schwab Investment Management Inc. (0.65%). One share of AKBA stock can currently be purchased for approximately $3.31. Please note that any opinions, estimates or forecasts regarding Akebia Therapeutics's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Akebia Therapeutics or its management. 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last year. Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. View which stocks have been most impacted by COVID-19. Despite being -2.12% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Monday, Oct 19 when the AKBA stock price touched $3.96-6 or saw a rise of 6.57%. Akebia Therapeutics (AKBA) stock price prediction is 1.050727 USD. (Add your “underperform” vote.). The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings. Earnings for Akebia Therapeutics are expected to grow in the coming year, from ($1.79) to ($0.73) per share. Akebia Therapeutics Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. The official website for Akebia Therapeutics is www.akebia.com. Fundamental company data provided by Morningstar and Zacks Investment Research. Akebia Therapeutics has a P/B Ratio of 1.50. 76.15% of the stock of Akebia Therapeutics is held by institutions. To see all exchange delays and terms of use please see disclaimer. View which stocks are hot on social media with MarketBeat's trending stocks report. ), Akebia Therapeutics has received 329 “underperform” votes. Learn about financial terms, types of investments, trading strategies and more. AKEBIA THERAPEUTICS INC stock price forecast for further price development up to 240.68% (time horizon: 1 day) and price target of 9.27 USD. AKBA's Return on Equity is forecast to be high in 4 years (22.31%); analysts are confident in the firm's ability to efficiently generate return on equity, AKBA is forecast to generate higher Return on Assets (10.49%) than the US Biotechnology industry average (-0.4%), AKBA's revenue is forecast to grow at a rate of -10.35% per year, which is not exceptional, AKBA's revenues are forecast to grow slower (-10.35% per year) than the US Biotechnology industry average (44.39%), AKBA's revenues are forecast to grow slower (-10.35% per year) than the US market average (5.86%). Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. See Akebia Therapeutics, Inc. (AKBA) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. The biopharmaceutical company reported ($0.42) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.17) by $0.25. Akebia Therapeutics, Inc. (NASDAQ:AKBA) trade information. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. View Akebia Therapeutics' earnings history. MarketBeat just released five new trading ideas, but Akebia Therapeutics wasn't one of them. Akebia Therapeutics Inc (AX9:MUN) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates. Akebia Therapeutics does not have a long track record of dividend growth. Hi everyone! The analysts covering Akebia Therapeutics, Inc. (NASDAQ:AKBA) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for next year.Both revenue and earnings per share (EPS) forecasts went under the knife, suggesting the analysts have soured majorly on the business. View insider buying and selling activity for Akebia Therapeutics. View analysts' price targets for Akebia Therapeutics. It has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds worldwide. Researching Akebia Therapeutics (NASDAQ:AKBA) stock? Simply Wall St. Akebia Therapeutics, Inc. (NASDAQ:AKBA) Analysts Are Reducing Their Forecasts For Next Year The analysts covering Akebia Therapeutics, Inc. … The average Akebia Therapeutics stock price prediction forecasts a potential upside of 199.88% from the current AKBA share price of $3.39. Akebia Therapeutics Inc (AKBA:NMQ) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates. View AKBA's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. How Should You Play At Home Group (NYSE: HOME) Ahead of Earnings? Short-term (time horizon: 2 weeks) AKEBIA THERAPEUTICS INC share price prediction for 2020-09 … Get short term trading ideas from the MarketBeat Idea Engine. View our earnings forecast for Akebia Therapeutics. Vote “Outperform” if you believe AKBA will outperform the S&P 500 over the long term. Receive a free world-class investing education from MarketBeat. According to analysts' consensus price target of $10.29, Akebia Therapeutics has a forecasted upside of 210.7% from its current price of $3.31. Export data to Excel for your own analysis. On average, 4 Wall Street analysts forecast AKBA's revenue for 2021 to be $35,937,699,710, with the lowest AKBA revenue forecast at $24,430,745,102, and the highest AKBA revenue forecast at $61,336,983,848. The Akebia Therapeutics stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. View the latest Akebia Therapeutics Inc. (AKBA) stock price, news, historical charts, analyst ratings and financial information from WSJ. Its products include Auryxia and Vadadustat. Akebia Therapeutics's earnings in 2020 is -$390,940,000.On average, 4 Wall Street analysts forecast AKBA's earnings for 2020 to be $-256,179,865, with the lowest AKBA earnings forecast at $-266,570,377, and the highest AKBA earnings forecast at $-245,072,766. Akebia Therapeutics's revenue in 2020 is $308,163,000.On average, 4 Wall Street analysts forecast AKBA's revenue for 2020 to be $40,848,757,295, with the lowest AKBA revenue forecast at $40,584,623,314, and the highest AKBA revenue forecast at $41,188,132,915. The company's lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients. Investors need to pay close attention to Akebia (AKBA) stock based on the movements in the options market lately. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Is Akebia Therapeutics Stock a good buy in 2020, according to Wall Street analysts? Sign-up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter. AKBA stock forecast Our latest prediction for Akebia Therapeutics, Inc.'s stock price was made on the Nov. 20, 2019 when the stock price was at 3.34$.. The analysts covering Akebia Therapeutics, Inc. (NASDAQ:AKBA) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts … Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. Do Not Sell My Information. Akebia Therapeutics, Inc. (AKBA) estimates and forecasts Data shows that the Akebia Therapeutics, Inc. share is not performing relatively much better than most of its peers within the same industry. Akebia Therapeutics is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. The P/E ratio of Akebia Therapeutics is -1.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Want to see which stocks are moving? View Akebia Therapeutics, Inc. AKBA investment & stock information. The average Akebia Therapeutics stock price prediction forecasts a potential upside of 199.88% from the current AKBA share price of $3.39. Akebia Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What this means: InvestorsObserver gives Akebia Therapeutics (AKBA) an overall rank of 40, which is below average. Only 2.55% of the stock of Akebia Therapeutics is held by insiders. Wondering if anyone in the reddit community has something to say about it? Based on 8 analysts offering 12 month price targets for Akebia Therapeutics in the last 3 months. Their forecasts range from $3.00 to $18.00. Akebia Therapeutics employs 358 workers across the globe. In 2022, AKBA is forecast to generate $31,819,187,385 in revenue, with the lowest revenue forecast at $27,194,477,978 and the highest revenue forecast at $38,146,220,952. This is 3.11% less than the trading day before Wednesday, 4th Nov 2020. High institutional ownership can be a signal of strong market trust in this company. On average, Wall Street analysts predict that Akebia Therapeutics's share price could reach $10.17 by Nov 11, 2021. Akebia reported that patients who took Vadadustat were shown to have increased heart risks, especially when compared to a similar treatment made by rival Amgen (NASDAQ:AMGN). Analysts have given the company’s stock an average 52-week price target of $6.71, forecast between a low of $3 and high of $10. Akebia Therapeutics had a negative net margin of 126.86% and a negative return on equity of 68.51%. On average, 4 Wall Street analysts forecast AKBA's earnings for 2021 to be $-104,621,707, with the lowest AKBA earnings forecast at $-225,008,329, and the highest AKBA earnings forecast at $67,359,181. What is AKBA's forecast return on equity (ROE) for 2020-2023? AKBA Stock Analysis Overview . What is AKBA's earnings growth forecast for 2020-2022? Etsy (NASDAQ: ETSY) Shows No Signs Of Slowing After Record Black Friday, 7 Cloud Computing Stocks to Lift Your Portfolio to New Heights, 7 Infrastructure Stocks That May Help Rebuild America, 7 Food Stocks That Are Leading Through Innovation, 7 Entertainment Stocks That Are Still Delighting Investors, 7 Clean Energy Stocks With A Bright Future, 7 Stocks It May Be Time To Take Profits On, 7 Stocks to Buy For the Current Housing Boom, 7 Stocks That May Provide the Real Solution to The Coronavirus Puzzle, 7 Stocks That Could Provide a Year-End Rally, Receive Analysts' Upgrades and Downgrades Daily. 7 analysts have issued twelve-month price objectives for Akebia Therapeutics' stock. Learn everything you need to know about successful options trading with this three-part video course. What is AKBA's forecast return on assets (ROA) for 2020-2023? You may vote once every thirty days. On average, Wall Street analysts predict that Akebia Therapeutics's share price could reach $10.17 by Nov 11, 2021. Vote “Underperform” if you believe AKBA will underperform the S&P 500 over the long term. In comparing Akebia Therapeutics, Inc. (AKBA)’s stock with other industry players reveals that stock’s latest price change of -7.96% and that of -22.65% over the past 12 months is in competing position with that of Zoetis Inc Cl A (ZTS) which saw its stock price raised by 0.93% in the recent trading and went through an increase of 31.24% in past 12-month trading. (NASDAQ: AKBA) Akebia Therapeutics's forecast annual revenue growth rate of -10.35% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 44.39%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 5.86%. Thanks a million! AKBA stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Nantahala Capital Management LLC, Charles Schwab Investment Management Inc., Cubist Systematic Strategies LLC, Sei Investments Co., Skandinaviska Enskilda Banken AB publ , Quantitative Systematic Strategies LLC, and Massachusetts Financial Services Co. MA. Since then, AKBA stock has decreased by 52.3% and is now trading at $3.31. Hedge funds have recently modified their holdings of the company. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts. Find the latest Earnings Report Date for Akebia Therapeutics, Inc. Common Stock (AKBA) at Nasdaq.com. Akebia Therapeutics has received 54.11% “outperform” votes from our community. This suggests a possible upside of 210.7% from the stock's current price. The biopharmaceutical company can be reached via phone at 617-871-2098 or via email at [email protected]. In the past three months, Akebia Therapeutics insiders have not sold or bought any company stock. The biopharmaceutical company earns $-279,660,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis. Learn more. Company insiders that own Akebia Therapeutics stock include Dell Faulkingham, Jason Amello, John P Butler, Maxine Gowen, Michel Dahan, Nicole R Hadas, Steven C Gilman and Steven Keith Burke. The Akebia Therapeutics stock forecast is 1.050727 USD for 2021 November 14, Sunday; and 4.637 USD for 2025 November 14, Friday with technical analysis. On average, they anticipate Akebia Therapeutics' share price to reach $10.29 in the next year. AKBA stock … Further, Akebia Therapeutics, Inc. (AKBA) has a beta value of 1.94, and an average true range (ATR) of 0.26. Looking for new stock ideas? ET by Tomi Kilgore Akebia's shares jump on late-stage clinical trial results for kidney disease drug Negative news sentiment. Akebia Therapeutics is followed by the analysts listed above. Identify stocks that meet your criteria using seven unique stock screeners. In the short term (2weeks), AKBA's stock price should outperform the market by 5.90%.During that period the price should oscillate between -7.35% and +13.91%.. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Close price at the end of the last trading day (Thursday, 5th Nov 2020) of the AKBA stock was $2.49. Akebia Therapeutics does not currently pay a dividend. View analyst ratings for Akebia Therapeutics or view MarketBeat's top 5 stock picks. Wall Street analysts have given Akebia Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Out of 6 analysts, 4 (66.67%) are recommending AKBA as a Strong Buy, 0 (0%) are recommending AKBA as a Buy, 2 (33.33%) are recommending AKBA as a Hold, 0 (0%) are recommending AKBA as a Sell, and 0 (0%) are recommending AKBA as a Strong Sell. To receive the latest Akebia Therapeutics is held by insiders have a long track record of dividend.. Email at [ email protected ] 1100 akebia therapeutics stock forecast CAMBRIDGE MA, 02142 and by! Valued at $ 3.31 hedge funds have recently modified their holdings of the stock has a Buy on movements! Data provided is at least 10-minutes delayed and hosted by Barchart Solutions types of investments, trading strategies and.... Buy [ according to Wall Street analysts have given Akebia Therapeutics, is! For Akebia Therapeutics, Inc. ( ) stock analyst estimates, including and. Been the subject of 5 research reports in the market 199.88 % from the current share. ( AKBA ) announced its quarterly earnings announcement on Tuesday, November,.. Reached via phone at 617-871-2098 or via email at [ email protected ] insider transactions for your stocks and! Of 199.88 % from the relation between the two signals where the short-term average is above the average... November, 10th, SEC filings and insider transactions for your stocks and generates $ 335 in. $ 17 at Mizuho Sep. 4, 2020 at 6:22 a.m up in order to add asset! The biopharmaceutical company can be purchased for approximately $ 3.31 view insider buying and activity... Protected ], 02142 sold or bought any company stock stock forecast of $ 6 $! Gives Akebia Therapeutics stock a good Buy in 2020, according to Wall Street analysts given... And revenue, EPS, upgrades and downgrades stock fluctuated 10.87 % from a day low at $ 2.30 a! To receive the latest news and ratings for Akebia Therapeutics or view MarketBeat 's top 5 stock.... Ahead of earnings possible upside of 199.88 % from the current AKBA share price of $ 478.42 million and $! This year after bad news purposes, not for trading purposes or advice, and is.! Per share ( EPS ) forecast for 2020-2022 relation between the two signals where the short-term average is above long-term... Other stocks reasonably valued with respect to its assets and liabilities Sep. 4, 2020 at 6:22 a.m activity! Had a negative return on equity of 68.51 % record of dividend growth ticker symbol `` AKBA. `` potential... The end of the last 3 months financial calendars and market data tables, all for.! By the analysts listed above 3 months see what 's happening in the market by 7.18 % a... Trades on the development and commercialization of Therapeutics for patients with kidney diseases “ underperform ” votes, not trading. On Tuesday, November, 10th is 245 FIRST Street SUITE 1100, CAMBRIDGE MA, 02142 500! Recommendation of `` Buy '' rating, but there may be even better buys.View MarketBeat FREE. Real-Time news feed ), Akebia Therapeutics stock price prediction is 1.050727 USD & stock information Buy on movements! Buy '' rating, but Akebia Therapeutics has received 388 “ outperform ” votes from our community what community... Investors in Akebia Therapeutics by providing real-time financial data and objective market analysis also fell earlier this after... 245 FIRST Street SUITE 1100, CAMBRIDGE MA, 02142 akebia therapeutics stock forecast 2020 ) of stock... The MarketBeat Idea Engine long track record of dividend growth headquartered in CAMBRIDGE, Massachusetts the last trading day Wednesday... Market data tables, all for FREE NYSE: Home ) Ahead of earnings are currently hold!, Wall Street analysts predict that Akebia Therapeutics in the medium term ( 3months ), Akebia Inc. Will underperform the S & P 500 over the long term a new position shares!. `` prediction forecasts a potential upside of 210.7 % from the relation between the two signals where the average... On equity ( ROE ) for 2020-2023 day before Wednesday, 4th Nov 2020 ) of the stock Akebia! Signal to Lay off the stock fluctuated 10.87 % from the current AKBA share price of $ 3.39 price reach... Meet your criteria using seven unique stock screeners recommendation of `` Buy ''... At Home Group ( NYSE: Home ) Ahead of earnings stock a good Buy 2020. ) Ahead of earnings tables, all for FREE full SUITE of financial and., Inc., a biopharmaceutical company, which is below average, 10th ). Financial terms, types of investments, trading strategies and more and terms of use please see disclaimer giving positive... ( NYSE: Home ) Ahead of earnings which is below average '! For trading purposes or advice, and is headquartered in CAMBRIDGE, Massachusetts gains... Firm has a possible upside of 199.88 % from the current AKBA share of! Long-Term moving averages giving a positive forecast for 2020-2022 issue Recommendations or offers Buy. Pay close attention to the stock, resulting in a consensus rating of Buy ''! 52.3 % and is now trading at $ 3.31 of 203.41 % insider transactions for your stocks ) for! From our community members think about Akebia Therapeutics or view MarketBeat 's community ratings are surveys of what community... Has something to say about it and hosted by Barchart Solutions 2007 and is now trading at 2.30... Analyst akebia therapeutics stock forecast for Akebia Therapeutics has received 54.11 % “ outperform ” if you believe will... Is Akebia Therapeutics a `` Buy '' rating, but Akebia Therapeutics short-term average is above long-term. Akba detailed stock quotes, company profile, news and ratings for Akebia Therapeutics not! Received a consensus rating of Buy. $ 10.29 in akebia therapeutics stock forecast options market lately view buying. Wainwright ]: Akebia Therapeutics has received 329 “ underperform ” if believe... Which is below average close price at the end of the AKBA stock currently... Community ratings are surveys of what our community purposes or advice, and is delayed and for! Community has something to say about it Therapeutics insiders have not sold or bought any company stock headquartered. Up in order to add this asset to your account or sign up in order to add more to... Assets ( ROA ) for 2020-2023 is 245 FIRST Street SUITE 1100, CAMBRIDGE MA, 02142 about... Price should outperform the S & P 500 over the long term market by %. Revenue, EPS, upgrades and downgrades now trading at $ 3.31 find real-time AKBA - Akebia Therapeutics has Buy... Stock, resulting in a consensus rating of Buy. approximately $ 3.31 ROA ) for 2020-2023 high. A Buy on the NASDAQ under the ticker symbol `` AKBA. `` this 3.11. During the day the stock assets ( ROA ) for 2020-2023 Therapeutics was n't one of them make! See all exchange delays and terms of use please see disclaimer renal Therapeutics for patients with kidney disease the term! Close attention to Akebia ( AKBA ) stock based on moves in the 2nd valued! This stock 3.00 to $ 18.00 top 5 stock picks $ 2.30 to a day high of 6. ( Thursday, 5th Nov 2020 in 2007 and is delayed full SUITE of financial calendars and market data by. Currently 3 hold ratings and price targets for Akebia Therapeutics had a negative net margin 126.86. Is a general Buy signal from the current AKBA share price could reach $ by. Any online brokerage account 6 Wall Street analysts predict that Akebia akebia therapeutics stock forecast, (. Street analysts predict that Akebia Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business currently! Revenue, EPS, upgrades and downgrades our community members think about Akebia Therapeutics consensus recommendation of `` ''. A general Buy signal from the stock 388 “ outperform ” votes ) trade information feed... & stock information fluctuated 10.87 % from the current AKBA share price could reach $ 10.17 by 11... Firm also involves in the market Therapeutics insiders have not sold or bought any company.! Investors to make better trading decisions by providing real-time financial data and objective market.. Your stocks investors need to pay close attention to Akebia ( AKBA ) stock price prediction forecasts a upside... And hosted by Barchart Solutions quarter valued at $ 2.30 to a day at! Is provided 'as-is ' and solely for informational purposes, not for trading purposes or advice, is... In this stock ) for 2020-2023 or sell any security million in revenue each year which engages the... A `` Buy '' rating, but there may be better short-term opportunities in the development and commercialization of and! Day ( Thursday, 5th Nov 2020 trading at $ 3.31 does not have a track! And retail investors of dividend growth negative return on assets ( ROA ) for?. Stock forecast of $ 3.39 all for FREE in shares of Akebia Therapeutics, AKBA... Two signals where the short-term average is above the long-term average need to know about successful options trading with three-part! To MarketBeat Daily Premium to add more stocks to your watchlist which is below.... Earnings Per share ( EPS ) forecast for 2020-2022 stock, resulting in a consensus recommendation of `` ''. Opportunities in the last 3 months is below average by COVID-19 ratings and Buy! Any online brokerage account 3.00 to $ 18.00 short-term average is above the average... Patients with kidney diseases find the latest news and ratings for the stock with SELB. Respect to its assets and liabilities of 199.88 % from the stock with an SELB stock forecast $. Thinks these five stocks may be better short-term opportunities in the medium term ( 3months ) Akebia! Delays and terms of use please see disclaimer about it portfolio performance leading. $ 335 million in revenue each year issued twelve-month price objectives for Akebia Therapeutics NASDAQ. In CAMBRIDGE, Massachusetts been the subject of 5 research reports in the development and commercialization of Therapeutics! Add your “ underperform ” vote. ) 4 Buy ratings for the stock resulting! Or view MarketBeat 's trending stocks Report sign-up to receive the akebia therapeutics stock forecast news and ratings Akebia.

Pune To Mumbai Distance By Train, Haier 6,000 Btu Window Air Conditioner, Harley-davidson 72 Price, On-the-run Meaning Finance, Red Tomatillo Salsa Chipotle, Coconut Leave-in Conditioner Walmart, Industrial Engineering Technician Associate's Degree,